期刊文献+

不同部位结直肠癌的血清肿瘤指标及中医分型 被引量:2

Serum Tumor Markers and Traditional Chinese Medicine Classification of Colorectal Cancer in Different Parts
下载PDF
导出
摘要 目的对不同部位结直肠癌的血清肿瘤指标及中医辨证分型进行比较分析。方法采用回顾性分析,对147例结直肠癌患者,根据原发肿瘤发生部位的不同,分为3组:左半结肠组,右半结肠组和直肠组,对各组的血清肿瘤指标及中医辨证分型进行比较分析。结果血清肿瘤指标CEA、CA125、CA50在各不同解剖部位结直肠癌的表达无明显差异;而CA199的表达差异具有统计学意义(P<0.05),右半结肠癌中CA199阳性率表达最高。湿热蕴结型在直肠癌中多见,与其他部位相比具有统计学意义(P<0.05)。肝肾阴虚型在右半结肠中多见,与其他部位相比具有统计学意义(P<0.05)。而脾虚气滞、瘀毒内阻、脾肾阳虚、气血两虚四个证型均在各组中无显著差异性(P>0.05)。结论在当前结直肠癌提倡个体化、精准化治疗时代,不同部位结肠癌的各种差异为结直肠癌的中西医结合诊疗提供指导,造福患者,使患者能够最大获益。 Objective To compare and analyze the serum tumor markers and TCM syndrome differentiation of colorectal cancer in different parts.Methods This was a retrospective analysis.147 patients with colorectal cancer was divided into 3 groups according to the location of the primary tumor;left colon group,right colon group and rectum group.The serum tumor markers and TCM syndrome differentiation of each group were compared and analyzed.Results There was no significant difference in the expression of serum tumor markers CEA,CA125 and CA50 in different anatomical parts.The expression of CA199 was statistically significant(P<0.05),and the positive expression of CA199 was the highest in right colon cancer.The damp-heat accumulation type was more common in rectal cancer,and it was statistically significant compared with other sites(P<0.05).Deficiency of the liver-yin and kidney-yin type was more common in the right colon,and it was statistically significant compared with other sites(P<0.05).The syndromes of spleen deficiency and qi stagnation,toxic stasis,insufficiency of both the spleen and the kidney,spleen and kidney yang deficiency,and qi-blood deficiency were not significantly different in each group(P>0.05).Conclusion In the current era of colorectal cancer advocated individualized and precise treatment,various differences in colon cancer in different parts provide guidance for the diagnosis and treatment of colorectal cancer with integrated Chinese and Western medicine,benefiting patients and maximizing patients'benefits.
作者 缪娴 MIAO Xian(Department of Oncology,Nantong Traditional Chinese Medicine Hospital,Nantong Jiangsu 226000,China)
出处 《中国继续医学教育》 2020年第18期155-157,共3页 China Continuing Medical Education
基金 2018年南通市卫生和计划生育委员会科研立项课题(名称:基于高通量测序技术之济生散配合结直肠癌化疗后肠道菌群的研究,编号:WKZL2018032)。
关键词 结直肠癌 左半结肠癌 右半结肠癌 直肠癌 中医辨证分型 肿瘤指标 colorectal cancer left colon cancer right colon cancer rectal cancer syndrome differentiation of traditional Chinese medicine tumor index
  • 相关文献

参考文献13

二级参考文献77

  • 1严小军,左铮云.中医对结肠癌前病变机理的探讨[J].辽宁中医杂志,2007,34(7):905-906. 被引量:27
  • 2Jemal A, Siegel R, Xu J, et al. Cancer Statistics, 2010 [J]. A Cancer Journal for Clinicians, 2010, 60(5): 277-300.
  • 3Ku GY, Haaland BA, Lima LG. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters [J]. Cancer Chemother Pharmacol, 2012, 70(2): 231-238.
  • 4Einem JC, Heinemann V, Weikersthal, et al. Left sided primary tumors are associated with favorable prognosis in patients with KRAS codon12/13 wild type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK?0104 trial [J]. J Cancer Res Clin Oncol, 2014, 140(9): 1607-1614.
  • 5Wu XC, Vivien W, Martin J, et al. Subsite-Specific Colorectal Cancer Incidence Rates and Stage Distributions among Asians and Pacific Islanders in the United States, 1995 to 1999 [J]. Cancer Epidemiol Biomarkers Prev, 2004, 13(7): 1215-1222.
  • 6Douillard JY, Oliner KS, Siena S, et al. Anitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer [J]. N Engl J Med, 2013, 369(11): 1023-1034.
  • 7Stintzing S, Heinemann V, Moosmann N, et al. The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status [J]. Deutsches Arzteblatt Int, 2009, 106(12): 202-206.
  • 8Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC:phase III trial of cetuximab plus irinotecan alter fluoropyrimidine and oxali- platin failure in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2008, 26(14): 2311-2319.
  • 9Curmingham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Eng J Med, 2004, 351(4): 337-345.
  • 10Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cemximab for the treatment of colorectal cancer [J]. N Eng J Med, 2007, 357 (20): 2040-2048.

共引文献208

同被引文献61

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部